Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 NeoStem’s Irvine Site Receives Manufacturing License | Contract Pharma

What are you searching for?

Sign in
Breaking News

NeoStem’s Irvine Site Receives Manufacturing License

Will produce immunotherapy for the treatment of melanoma

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

NeoStem, Inc. has received a drug manufacturing license following a successful review of its Irvine, CA cGMP facility by the State of California’s Department of Public Health, Food and Drug Branch. NeoStem will produce eltrapuldencel-T (also known as NBS20) from this facility, including the manufacture of eltrapuldencel-T for clinical trial use. Eltrapuldencel-T is the company’s patient-specific targeted cancer immunotherapy under investigation for the treatment of Stage IV or recurrent Stage III metastatic melanoma.
 
Eltrapuldencel-T is an autologous immunotherapy intended to eliminate cancer-initiating (stem) cells capable of causing disease recurrence and progression. Creation of the therapy begins with cancer-initiating (stem) cells that have been isolated from the patient’s resected tumor sample, enriched and inactivated, combined with dendritic cells (antigen-presenting immune cells), and then introduced back into the patient via a series of subcutaneous injections.
 
“We are pleased to have reached another critical milestone in the development of NBS20. With this step, we remain on track to begin patient enrollment in our pivotal Phase 3 trial, the Intus Study, to evaluate eltrapuldencel-T in metastatic melanoma, during the first quarter of 2015,” said Dr. David J. Mazzo, chief executive officer of NeoStem.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics